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Khoynezhad A, Donayre CE, Smith J, Kopchok GE, Walot I, White RA. Risk factors for early and late mortality after thoracic
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The above-noted article was read at the Thirty-third Annual Meeting of the Western Thoracic Surgical Association, Santa Ana
Pueblo, New Mexico, June 27–30, 2007.
The accompanying ‘‘Discussion’’ was not printed with the original article in the May 2008 issue, but is printed here.
Discussion
Dr Mitchell (Stanford, Calif). Dr Khoynezhad, you are to be congratulated on a nice presentation and a nicely analyzed
series.
I think the presentation pretty much speaks for itself. I will not rehash it, but instead let us dig a little deeper as to the things we
need to know about.
I think patient selection is one of the primary variables in who is appropriate for an endovascular repair. I wonder if you could
help us in that way by elucidating how many patients in this same time interval were treated by open techniques and what
criteria you use to decide between open and endovascular repair?
Dr Khoynezhad. This study was performed at Harbor-University of California Los Angeles Medical Center, where I had my
endovascular training. The majority of patients with aortic pathologies underwent endovascular procedures. A cardiothoracic
surgeon at the local institution provided open repair for a few patients. The majority patients in this study were referred from
outside facilities with significant comorbidities. They were not deemed surgical candidates, as assessed by a cardiothoracic or
vascular surgeon experienced in open repair.
Dr Mitchell. This information about type 1 endoleaks as the primary determinant of early mortality is an important one. The
question is, is there a way to preoperatively identify the patient who is at greatest risk for developing a type 1 endoleak? Did you
look at the length of landing zone, size of landing zone, and angulations, the things that can help in the preoperative selection to
know who is not going to be a good candidate?
Dr Khoynezhad. That is an excellent question. Obviously the most important risk factors for type I endoleak is adequate
proximal and distal landing zone. All stent graft manufacturers require a 2-cm landing zone, and if that is not the case on
preoperative imaging that patient should not be offered an endovascular repair.
The risk factors for type I endoleak also include improper stent graft size selection. That can happen in inexperienced hands that
look solely to the computed tomography scan or angiogram. Intravascular ultrasound is a sensitive imaging modality that is
helpful in reducing the sizing mishaps, and I think all thoracic surgeons should be using that as part of their armamentarium.
Improper sizing causes oversizing or undersizing of stent grafts within the aortic lumen, both contributing significantly to type I
endoleak.
Other risk factors for type I endoleak are thrombus or significant calcification on the proximal and distal landing zone. These
need to be identified on the preoperative imaging. I think an important message of this study is that preoperative imaging and
planning of the procedure are crucial parts of an endovascular procedure, and they need to be done by an experienced team and
according to the accepted endovascular criteria. Patients with inadequate length and angulation of the landing zones should be
strongly considered for an open surgical option (if they are open repair candidates), because they are at higher risk of type I
endoleak and therefore higher mortality.
Dr Mitchell. Do you think that most of these patients had a landing zone of 2 cm or greater?
Dr Khoynezhad. I have to look into that data to give you specific details. All patients had a proximal landing zone that was
according to the instruction for use (IFU) of the manufacturer. Our inclusion criteria included aneurysms greater than 5 cm and
symptomatic or complicated acute and chronic type B dissections, and transections in patients who had anatomy suitable for
endovascular repair. Patients with connective tissue disorder, patients who were younger than 18 years, and patients who were
pregnant were excluded. Having said that, having the criteria suitable for endovascular repair does not mean that they are perfect
candidates, because they may have significant calcification in the landing zones contributing to type I endoleak. By using in-
travascular ultrasound we can classify the aortic arch calcification according to the classification from New York University. A
grade 3 to 5 calcification in the transverse and proximal descending aorta will predict the probability of stroke and potential for
type I endoleak.
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DrMitchell. I noted at least to my reading it looked like there were 6 retrograde type A dissections. This certainly is a lot higher
than in our experience, and I wonder if you could offer us any insight as to the mechanisms. Is that from having a stiff sheath up
in the arch? Does this occur doing that large of a balloon inflation? Do you have any insights as to the mechanism?
DrKhoynezhad. There were 4 patients with retrograde dissections. They were counted while evaluating proximal endoleaks as
well as dissection. Three patients with retrograde dissection expired, and another patient required emergency operation by the
local cardiothoracic surgeon, and the patient was discharged without significant sequela. In terms of mechanism of retrograde
dissection, we are still working with first-generation stent grafts. The majority of the stent grafts that were used here have a bare-
metal spring on the proximal end that can produce a dissection in patients with a friable aorta. The patients with acute or chronic
dissection are at higher risk for retrograde dissection, especially if the stent grafts have bare springs at the proximal or distal end.
Dr Craig Miller (Stanford, Calif). Number one, let me congratulate you. The Harbor Torrance group has told us that endo-
vascular stent grafting is not a walk in the park. It is a bad disease and the results are bad, let’s be honest.
I do not think you satisfied my curiosity with respect to Dr Mitchell’s question: How many patients in the 7 years at Harbor
Torrance underwent an open repair and what were the results? It is hard to believe they were any worse than what you have
just presented.
DrKhoynezhad. I do not have the information about the open repairs. In terms of long-term follow-up, we know endovascular
repair will not improve long-term survival.
Dr Miller. I am talking about stroke, paraplegia, and death.
Dr Khoynezhad. I do not have the results of open repair. Having said that, compared with open repair, the stroke rate in our
study is similar to that of open repair, when looking at the results of most large retrospective studies on aortic pathologies. Para-
plegia is definitely lower.
Dr Miller. You do not have the numbers.
Dr Khoynezhad. As I said, I do not have the numbers.
Dr Miller. Okay, who does open descending thoracic aortic repairs at Harbor Torrance?
Dr Khoynezhad. Dr Bassam Omari is the local cardiothoracic surgeon.
DrMiller. It’s not good, and the question you beg is what did you learn from this experience? Aside from what you just said to
Dr Mitchell, you used stent grafts that I would not put in a thoracic aorta of my worst enemy’s dog. These stent grafts were not
designed to be in the thoracic aorta of a human being, let alone your worst enemy’s dog. Some of them are still being pushed
today. They involve obsolete sheath dilator technology that we learned 12 years ago is a mistake, and we have newer stent
grafts. The Food and Drug Administration, as you know, is currently weighing 1 or 2 of these, the Cook TX2 and the Medtronic
Talent, now called Valiant in Europe. What did you learn from your experience about the type of graft, character of landing
zones, and just generalized ‘‘this patient is going to die and I don’t want that patient to die on my watch.’’ What did you learn
from this experience?
Dr Khoynezhad. As I mentioned, preoperative planning is very important. Endovascular repair has reduced operative mortal-
ity and morbidity in a selected patient population in the Gore TAG trial. However, the long-term outcomes were equal at 2 years,
suggesting that significant comorbid conditions in this patient population are dominating long-term results. Therefore for an-
eurysms, I think we have the answer. Aortic transections, although there are no studies comparing those, are a relatively easy
call because endovascularly some of those cases take 50 minutes from skin to skin, and they do not require high-dose heparin-
ization. The patients with brain injury or liver laceration can benefit significantly from this means of repair. I think an endo-
vascular stent is the way to go for these patients, and it is not going to change in the future to come. With open repair, as
you know, we have a 10% paraplegia rate. There is not a single paraplegia rate reported with endovascular worldwide with
aortic transection.
Dr Miller. That is not true, sir.
Dr Khoynezhad. Which one would that be?
Dr Miller. Paraplegia has been reported, but although you are talking about acute transections, what do you do with an 18 or
20-mm aorta when our smallest commercially available stent graft is way too big and you are going to buckle and they do not
have good access?
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Dr Khoynezhad. We do the same thing that vascular surgeons and cardiothoracic surgeons around the country, including the
ones in Stanford do. It is using abdominal aortic extenders or cuffs. These cuffs have a smaller diameter and are the only ones
that are currently available for an 18 to 22-mm aorta. Unfortunately, they are shorter in length and therefore predispose the
patient to type III endoleaks. Having said that, we do not have any better options and grafts available at this time.
DrMiller. Finally, what about chronic dissections? You have shown us some pretty sobering results with (retro-A) dissections,
perhaps due to the type of stent graft used, perhaps due to patient selection. Most authorities around the world have abandoned
stent grafting for chronic dissection. What is your current posture or Rod White’s current posture—both, yours and his, now that
you are out on your own? You are in Lincoln now, right?
Dr Khoynezhad. Actually, I work in Omaha. I did my open repair training before my endovascular training, so I do all my
chronic dissections open, including thoracoabdominal aneurysms. In terms of selection for chronic type B dissections, the pa-
tients had symptoms of malperfusion, including increasing creatinine or potentially increasing bowel ischemia symptoms or
abdominal pain. Furthermore, patients with chronically enlarged aneurismal degeneration of chronic type B aortic dissection
were included, who were not surgical candidates. A lot of these patients are O2 dependent with severe chronic obstructive pul-
monary disease and were not good candidates for open thoracotomy or thoracoabdominal operations. Those patients at high risk
for open repair, who are at high risk for rupture, were offered endovascular repair. I do not agree with the notion that the majority
of endovascular centers do not offer endovascular repair for chronic type B aortic dissection. I think in Europe it is much more
prevalent than here, as the recent published series suggested. Having said that, the long-term results are not clear, and it has not
been studied. For that reason I will not stent chronic dissections in my own personal series.
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The authors report two errors in the article: The percentage data were misplaced in the sixth line of the ‘‘Results’’ section of the
Abstract and the last line on page 635. The mistakes were the same. They should read as follows: The 5-year survivals were
15.5% and 52.5% for patients with and without lymph node metastasis, respectively (P, .001).
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supporting function of genetically modified swine lungs in baboons. J Thorac Cardiovasc Surg. 2007;133:1354-63.
The spelling of the last name of Dr. Schuurman was incorrect. The correct spelling is shown in the author line, above.
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San Juan R, Chaves F, Lo´pez Gude MJ, Daiz-Pedroche C, Otero J, Cortina Romero JM, Rufilanchas JJ, Aguado JM. Staph-
ylococcus aureus posternotomy mediastinitis: Description of two distinct acquisition pathways with different potential preven-
tive approaches. J Thorac Cardiovasc Surg. 2007;134:670-6.
The Conclusions section in the abstract in the above-noted article should read as follows:
Endogenous nasal colonization often precedes methicillin-susceptible S aureus poststernotomy mediastinitis, which suggests
that preoperative decontamination is adequate for preventing methicillin-susceptible S aureus poststernotomy mediastinitis,
whereas hospital infection control measures seem to be the major factor for preventing exogenous methicillin-resistant S aureus
poststernotomy mediastinitis.
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